This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
4 Citations 8 Q&As
Facts about Kallikrein-6.
Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position.
Shows action against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen.Degrades alpha-synuclein and prevents its polymerization, indicating that it may be involved in the pathogenesis of Parkinson disease and other synucleinopathies. May be involved in regulation of axon outgrowth following spinal cord injury.
Human | |
---|---|
Gene Name: | KLK6 |
Uniprot: | Q92876 |
Entrez: | 5653 |
Belongs to: |
---|
peptidase S1 family |
Bssp; EC 3.4.21; EC 3.4.21.-; hK6; kallikrein 6 (neurosin, zyme); Kallikrein 6; kallikrein-6; kallikrein-related peptidase 6; KLK6; Klk7; Neurosin; Protease M; protease, serine, 18; PRSS18; PRSS9; PRSS9MGC9355; Serine protease 18; Serine protease 9; SP59; Zyme
Mass (kDA):
26.856 kDA
Human | |
---|---|
Location: | 19q13.41 |
Sequence: | 19; NC_000019.10 (50958631..50969598, complement) |
In fluids, highest levels found in milk of lactating women followed by cerebrospinal fluid, nipple aspirate fluid and breast cyst fluid. Also found in serum, seminal plasma and some amniotic fluids and breast tumor cytosolic extracts. Not detected in urine. At the tissue level, highest concentrations found in glandular tissues such as salivary glands followed by lung, colon, fallopian tube, placenta, breast, pituitary and kidney. Not detected in skin, spleen, bone, thyroid, heart, ureter, liver, muscle, endometrium, testis, pancreas, seminal vesicle, ovary, adrenals and prostate. In brain, detected in gray matter neurons (at protein level). Colocalizes with pathological inclusions such as Lewy bodies and glial cytoplasmic inclusions. Overexpressed in primary breast tumors but not expressed in metastatic tumors.
Secreted. Nucleus, nucleolus. Cytoplasm. Mitochondrion. Microsome. In brain, detected in the nucleus of glial cells and in the nucleus and cytoplasm of neurons. Detected in the mitochondrial and microsomal fractions of HEK-293 cells and released into the cytoplasm following cell stress.
The best way to use an Anti-Kallikrein-6 antibody is to conduct an Western blot analysis using the boster bio KLK6 anti-body. This Boster Bio antibody is able to react with human mouse, rat, and KLK6. It is a good option for WB applications because of its specificity and cost-effectiveness. It is more expensive than other antibodies. To save money, think about using a diluted anti-KLK6 antibody.
A new polyclonal antibody has been created to recognize KLK6 with high affinity and specificity. This antibody can be used to diagnose and identify various neurological disorders and cancer. It has been shown to lessen the signs of disease in multiple sclerosis models mice. The anti-KLK6 marker is currently available for sale. Read more about Anti-Kallikrein-6/KLK6 Marker Boster Bio
Boster Immunoleader developed the KLK6 ELISA Kit. It is located in Pleasanton, CA. The kit uses an ELISA method to determine the concentration of KLK6 proteins in a sample. The results are expressed in picograms per milliliter of the media. The reaction time was about 30 minutes. Positive results indicate that the sample is protein-rich.
The anti-Kallikrein-6/KLR6 antibody can be used for a variety of applications, including cytokine screening, cancer diagnosis, and immunotherapy. It attaches to human Kallikrein in plasma, which allows for the identification of abnormally expressed cells and tissue. It is also useful for discovering the cause of cancer, which has been connected to Kallikrein.
Human KLK6 was first identified as protease M. This protein has been linked to various cancers due to its high level of expression as well as its potential biomarker function. The protein is released as a proenzyme and may be involved in CNS inflammation. Although its role in different conditions is not clear, it has been implicated in demyelination and inflammatory processes.
Caco-2 cells were used to create an anti-KLK6 marker. This cell line is highly expressed within Caco-2 cells. The Caco-KLK6 cell line was used to test its effects. This cell line has KLK6 in the membrane. This antibody is extremely specific and pinpoints KLK6 as the target.
The activation of KLK6 by SMAD signaling is a key characteristic of EMT. It triggers SMAD phosphorylation and promotes the expression of EMT markers. Thus, if examining the expression levels of this protein in your lab, the antibody may be helpful. Its bioactivity is confirmed by multiple independent studies. It detects the levels of proteins of various tumor samples after it is in the blood.
A study of breast cancer cell lines has revealed that the presence of the KLK6 marker significantly increased the risk of breast cancer metastasis. It is also believed to play an important role in EMT that encourages tumor invasion. We have shown that the KLK6 gene regulates expression of KRT8 (a tumor-causing gene) and KRT18 (a tumor-causing gene). We also discovered that the expression of KRT8 and KRT18 was inversely correlated with high levels of KLK6.
KLK6 is one of the genes that is heavily expressed in the CNS and has been linked to numerous neurological disorders. It is thought that its abnormal levels may contribute to the production of amyloidogenic fragments (AD) in Alzheimer's disease.
KLK6 is found in neuroendocrine tissue, including the islets and Langerhans, adrenal glands, and anterior pituitary. KLK6 can also be seen in rodent models for SCI and strokes caused by ischemic injury. KLK6 can be used to identify neurodegeneration that is a result of disease. However it is important to keep in mind that the exact expression of KLK6 in different tissues will produce different results.
As KLK6 is present in both bound and free forms in biological fluids it has been proven that it performs better as a biomarker of ovarian cancer. Although this study is only an initial study this new biomarker might be a useful tool for doctors. The study is currently being conducted in the United States. It is the only study to prove this conclusion. The results are promising and could serve as a foundation for future clinical research.
The specificity of the KLK6 marker has not been confirmed. It isn't known if it is more reliable than KLK5 or KLK7 in predicting outcomes for the head and neck squamous squamous cell cancer. It is a biomarker that can be used to identify early and predict favorable prognosis. But, KLK6 hasn't been considered in a lot of studies of head and neck cancer.
The KLK6 protein has been found to be linked with apoptosis-mediated proteins, such as BCLs. This could be the reason behind the decreased tumorigenicity of C28 cells. It is also associated with an increase in the expression of S100 proteins within lung cancer cells. In breast cancer clinical trials, overexpression of KLK6 was associated with poor outcomes. In addition, KLK6 gene's overexpression led to increased cell motility, which led to an increase and reduced expression of apoptosis-related proteases.
The most frequently-asked concern about the price of KLK6 is If it's worth it? This marker is found in the anterior pituitary and Langerhans islets and is linked to the production of insulin. Although the exact function of KLK6 is not yet known however, it could be involved in the regulation of cell physiology as well as pathophysiological responses. It is difficult to detect this marker with a cost-effective approach.
Researchers used four databases to determine the price of KLK6. They picked genes that were related to the marker and included in STRING, KOA, and GeneCard. The genes were then analysed by overlap analysis. Genes that were crossed were highlighted in red. After the elimination of duplicates and 105 genes, they were found to be closely with the KLK6 gene. After this was done the researchers created a visual diagram using R.
The cost of the KLK6 marker can differ based on whether it's used in a clinical trial. However, there are two types that are available to patients who have been positive or have had negative results. For women who have advanced breast cancer, the test can aid in determining if their cancer advanced or did not. While most people are pleased with the price of the KLK6 genetic test, it is expensive. It can be used to determine the possibility of developing a particular kind of cancer.
The high level of expression of KLK6 genes in pancreatic cancer is another reason for the price. The KLK6 gene may be involved in the development of pancreatic cancer. Although the KLK6 gene isn't overexpressed in the normal ovarybut it is significantly expressed in cancer patients with ovarian ovaries and is a significant indicator of the condition. There isn't a reliable test to identify the KLK6 gene because its expression is highly individual.
High levels of KLK6 in tumors is associated with poor patient outcomes. The KLK6 marker is an attractive potential target for developing new cancer therapies. Potent inhibitors of KLK6 activity may be used in the treatment of cancer. Only two potent inhibitors of KLK6 activity have been discovered to date. We will discuss their mechanism of action and clinical applications. Learn more about the KLK6 marker's benefits.
The target DNA sample should be taken from the ovarian or brain tissue in order to make the test as accurate and as sensitive as is possible. The primers were created to the anneal of a common region in the KLK6 DNA mRNA. Then Amplification of the DNA template was carried out. Two independent observers then viewed the PCR product. The results were then compared using the microarray.
A KLK6 transgenic mouse in mice promotes inflammation reminiscent of psoriasis via PAR1 signaling. This pathway could be targeted to provide a cytokine-independent treatment for psoriasis. Normalizing the levels of murine KLK6 reverses the process of inflammation in bone and PsA-affected adults. Further research into this effect could provide additional understanding.
The KLK6 marker may not be as sensitive as HE4 or CA125 but it does have comparable performance to other biomarkers. The AUC for all biomarkers with the same set of specificities is identical to the AUC for CA125 or HE4, which have higher sensitivity. The sensitiveness of the KLK6 marker was lower than that for the latter two.
Patient survival was linked to the mRNA and protein expression levels of KLK6. The higher the level of KLK6 protein, the higher the risk of survival without progression or death. Moreover, high levels of KLK6 mRNA were associated with a lower survival. The mRNA and protein levels were observed to have a significant positive correlation, but the relationship was not statistically significant. In addition, KLK6 expression is not associated with the remaining tumor mass.
PMID: 8898378 by Anisowicz A., et al. A novel protease homolog differentially expressed in breast and ovarian cancer.
PMID: 9003450 by Yamashiro K., et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain.
*More publications can be found for each product on its corresponding product page